Evidence map›Paper›PMID 33118384›Full record

ReviewCancer control : journal of the Moffitt Cancer Center

Magnetic Resonance Guided Radiotherapy for Rectal Cancer: Expanding Opportunities for Non-Operative Management.

Leila T Tchelebi, Paul B Romesser, Sebastian Feuerlein, Sarah Hoffe, Kujtim Latifi, Seth Felder, Michael D Chuong

Open access · goldAbstract readReview
In one paragraph

Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  5. Review
  6. Advances in radiation oncology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Leila T TchelebiDepartment of Radiation Oncology, Penn State College of Medicine, Hershey, PA, USA.ORCID https://orcid.org/0000-0002-4789-449X
Paul B RomesserDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sebastian FeuerleinDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA.
Sarah HoffeDepartment of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Kujtim LatifiDepartment of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Seth FelderDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Michael D ChuongDepartment of Radiation Oncology, Miami Cancer Institute, Miami, FL, USA.
Moffitt Cancer Center · USMemorial Sloan Kettering Cancer Center · USPenn State Milton S. Hershey Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Colorectal cancer is the third most common cancer in men and the second most common in women worldwide, and the incidence is increasing among younger patients. 30% of these malignancies arise in the rectum. Patients with rectal cancer have historically been managed with preoperative radiation, followed by radical surgery, and adjuvant chemotherapy, with permanent colostomies in up to 20% of patients. Beginning in the early 2000s, non-operative management (NOM) of rectal cancer emerged as a viable alternative to radical surgery in select patients. Efforts have been ongoing to optimize neoadjuvant therapy for rectal cancer, thereby increasing the number of patients potentially eligible to forgo radical surgery. Magnetic resonance guided radiotherapy (MRgRT) has recently emerged as a treatment modality capable of intensifying preoperative radiation therapy for rectal cancer patients. This technology may also predict which patients will achieve a complete response to preoperative therapy, thereby allowing for more appropriate selection of patients for NOM. The present work seeks to illustrate the potential role MRgRT could play in personalizing rectal cancer treatment thus expanding the role of NOM in rectal cancer.

Indexed as

Magnetic Resonance Imaging, InterventionalClinical Decision-MakingDisease-Free SurvivalHumansNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPatient SelectionProctectomyRadiotherapy, Image-GuidedRectal NeoplasmsRectumadaptive radiation therapychemoradiationquality of liferadiation therapyrectal cancer

Identifiers

PMID33118384
PMCPMC7791447
OpenAlexW3094820926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.